Moffitt logo
calledFromCancerPage=False - substr=
testProtocol=

Clinical Trials Search

Search Results:

Order By: 

Showing of 50

CLINICAL TRIAL 19627

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19715

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19829

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20069

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy

Disease Site: Non-Hodgkin's Lymphoma, Lymphoma

View Trial Details

CLINICAL TRIAL 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20608

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20737

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release

Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20751

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21094

An Open Label, Multi-Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination with Chemotherapy in Patients with Advanced T-cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21096

A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21580

A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21623

A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20397

A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21752

Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes

Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Hematopoietic

View Trial Details
;